Pharmascience Looks Back At First Year Of New CDMO Unit

Pharmascience’s John Foy Discusses The Company’s Latest Efforts And Plans

 
• By Adam Zamecnik

Almost a year since the establishment of an expanded CDMO business unit, Canada’s Pharmascience has doubled down on its plans to expand its presence through the pharmaceutical industry.

Pin of Canadian flag on a map
(Shutterstock)

Since the changing of its CEO at the start of 2023, the Canadian generics manufacturer Pharmascience has pushed onwards in its efforts to grow its presence in the pharmaceutical industry.

In a September 2023 exclusive interview with Generics Bulletin, Pharmascience’s then recently appointed CEO Martin Arès

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Interviews

More from Generics Bulletin